Skip to content

Comparison of Prognostic Effects of Lumbar Drainage with Continuous Catheterization and Intermittent Lumbar Drainage in Patients with Postoperative Aneurysmal Subarachnoid Hemorrhage: A Prospective, Single-center ,Controlled Clinical Trial

Comparison of Prognostic Effects of Lumbar Drainage with Continuous Catheterization and Intermittent Lumbar Drainage in Patients with Postoperative Aneurysmal Subarachnoid Hemorrhage: A Prospective, Single-center ,Controlled Clinical Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096647
Enrollment
Unknown
Registered
2025-01-27
Start date
2024-12-01
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aneurysmal subarachnoid hemorrhage

Interventions

Intervention group:Intermittent Lumbar Drainage
Control group:Continuous Lumbar Drainage

Sponsors

the Affiliated Hospital of Southwest Medical Univers
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1: Age >=18 and <=70 years. 2: Modified Rankin Scale (mRS) score <=1 before the current event. 3: Subarachnoid hemorrhage (SAH) due to ruptured intracranial aneurysm confirmed by computed tomography angiography (CTA) or digital subtraction angiography (DSA). 4: Underwent surgical treatment for the ruptured aneurysm. 5: Patient and/or legal guardian provided informed consent for LD treatment. 6: Patient and/or legal guardian agreed to long-term follow-up. 7: Patient and/or legal guardian provided written informed consent after fully reading and understanding the patient information sheet.

Exclusion criteria

Exclusion criteria: 1: Age 70 years. 2: Presence of unruptured intracranial aneurysms. 3: SAH due to traumatic or infectious aneurysm rupture. 4: History of hemorrhagic stroke. 5: History of hydrocephalus. 6: History of coagulopathy. 7: Presence of other severe intracranial diseases, including but not limited to: moyamoya disease, arteriovenous malformation (AVM), arteriovenous fistula (AVF), and malignant brain tumors. 8: Presence of other severe comorbidities, including but not limited to: severe depression, cancer (with a high likelihood of death within 2 years), and multi-organ failure. 9: Patient or legal guardian refused treatment. 10: Currently enrolled in other clinical trials with interventions that could interfere with the results of this study. 11: Any other condition deemed unsuitable for participation by the investigator.

Design outcomes

Primary

MeasureTime frame
Modified Rankin Scale;

Secondary

MeasureTime frame
Incidence of other complications related to subarachnoid hemorrhage (mainly including: rerupture hemorrhage, fever, cerebral vasospasm, cerebral vasospasm related cerebral infarction, etc.);Incidence of shunt dependent hydrocephalus;

Countries

China

Contacts

Public ContactJianhua Peng

Department of Neurosurgery, the Affiliated Hospital of Southwest Medical Univers

pengjianhua@swmu.edu.cn+86 152 2828 5418

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 10, 2026